Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

12.69 2.91 −18.65%
Market cap
$137.1M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(19.18%) (10.14%) (11.17%) (13.08%)
Piotroski F-Score
6 6 6 5
ROA
(12.79%) (6.64%) (7.40%) (8.81%)
ROIC
(75.01%) (61.14%) (37.52%) (50.66%)
Return on Tangible Assets
(21.52%) (10.59%) (11.89%) (14.11%)
Average Days of Receivables
127.63 114.74 116.89 126.29
Free Cash Flow per Share
(0.37) (1.52) (0.05) (0.02)
Free Cash Flow
(4.01) (16.19) (5.07) (2.21)
Capital Expenditures
— (12.13) — —
Other line items
Cash ROIC
(2.76%) (11.12%) (3.52%) (1.63%)
Accounts Receivable Turnover
2.98 3.42 3.25 2.83
Accounts Payable Turnover
4.73 3.74 5.01 5.26
Inventory Turnover
2.32 2.52 2.25 2.86
Average Days of Payables
88.33 108.82 50.35 51.47
Days of Inventory on Hand
140.35 129.74 151.50 97.85
Tax Rate
0.05 0.03 0.03 0.02
Research and Development Expense of Revenue
33.96% 30.86% 29.86% 27.03%
Selling, General and Administrative Expense of Revenue
55.22% 53.98% 56.06% 60.42%
Share Based Compensation of Revenue
0.00% 139.20% 0.00% 0.00%
Interest Coverage
(9.48) (6.00) (15.14) (1,191.25)
Operating CF/Net income
0.25 0.51 0.59 0.22
Depreciation/Fixed assets
0.00 10.58 0.00 0.00
Capex/Depreciation
— (0.26) — —
Revenue per Share
6.85 7.26 0.71 0.68
Operating CF per Share
(0.37) (0.38) (0.05) (0.02)
Capex per Share
0.00 (1.14) 0.00 0.00
Capex to Sales
0.00 0.16 0.00 0.00

Fold the line items

Columns are period end dates